Ready to discover the standout stock of 2024? We've identified a single buy & hold gem that's poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.
Get Your Free Report |
|
| I had to drop everything for this (no choice) (ad) |
|
- CEO Mark Zuckerberg sold 16,702 shares of Meta Platforms stock in a transaction on Friday, August 9th. The shares were sold at an average price of $513.09, for a total value of $8,569,629.18. Following the transaction, the chief executive officer now owns 98,654 shares in the company, valued at approximately $50,618,380.86. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
- (8/13) Market Volatility Continues: 4 Tech Stocks to Buy on the Dip (zacks.com)
- (8/13) Nasdaq Sell-Off: Buy the Dip on This "Magnificent Seven" Stock Before It Takes Off (fool.com)
- (8/13) Meta welcomes Turkey lifting access ban on Instagram, spokesperson says (reuters.com)
- (8/13) Meta Faces Legal Challenge From Polish Billionaire Over Fake Ads (msn.com)
- (8/13) Mark Zuckerberg Sells 16,702 Shares of Meta Platforms, Inc. (NASDAQ:META) Stock (insidertrades.com)
- (8/12) D.B. Root & Company LLC Acquires 1,184 Shares of Meta Platforms, Inc. (NASDAQ:META) (marketbeat.com)
- (8/12) Insider Selling: Meta Platforms, Inc. (NASDAQ:META) CEO Sells 16,702 Shares of Stock (marketbeat.com)
- (8/12) Prediction: 2 Stocks That Will Be Worth More Than Microsoft 10 Years From Now (fool.com)
- (8/12) Tuesday's big stock stories: What's likely to move the market in the next trading session (cnbc.com)
- (8/12) 3 Augmented Reality Stocks That Could Enhance User Experiences (investorplace.com)
- Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $6.88 price target on the stock, up previously from $2.00. This represents a 87.5% upside from the current price of $3.67.
- Ducommun (NYSE:DCO) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $80.00 price target on the stock, up previously from $64.00. This represents a 23.0% upside from the current price of $65.06.
- Dell Technologies (NYSE:DELL) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $97.00 price target on the stock. This represents a 3.5% downside from the current price of $100.53.
- First Industrial Realty Trust (NYSE:FR) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $64.00 price target on the stock. This represents a 19.2% upside from the current price of $53.70.
- Hormel Foods (NYSE:HRL) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $37.00 price target on the stock, up previously from $33.00. This represents a 16.2% upside from the current price of $31.84.
- Littelfuse (NASDAQ:LFUS) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $280.00 price target on the stock, up previously from $270.00. This represents a 14.0% upside from the current price of $245.51.
- Alliant Energy (NASDAQ:LNT) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $62.50 price target on the stock, up previously from $50.00. This represents a 11.2% upside from the current price of $56.19.
- Starbucks (NASDAQ:SBUX) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $110.00 price target on the stock, up previously from $81.00. This represents a 16.9% upside from the current price of $94.07.
- Starbucks (NASDAQ:SBUX) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $103.00 price target on the stock, up previously from $85.00. This represents a 9.5% upside from the current price of $94.07.
- Starbucks (NASDAQ:SBUX) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating. They now have a $105.00 price target on the stock, up previously from $81.00. This represents a 11.6% upside from the current price of $94.07.
- ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $22.00 price target on the stock, up previously from $18.00. This represents a 80.0% upside from the current price of $12.22.
- View today's most recent analysts' upgrades at MarketBeat.com
| Apple's Silent Suppliers Could Soar Through a Recession (ad) |
The iPhone has been Apple's #1 product for over a decade…
But it may not even exist as we know it by September 10.
Here's Why |
|
- Academy Sports and Outdoors (NASDAQ:ASO) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating. They now have a $54.00 price target on the stock, down previously from $58.00. This represents a 8.2% upside from the current price of $49.92.
- CenterPoint Energy (NYSE:CNP) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $28.00 price target on the stock, down previously from $32.00. This represents a 8.4% upside from the current price of $25.82.
- Cytokinetics (NASDAQ:CYTK) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $60.00 price target on the stock, down previously from $85.00. This represents a 10.5% upside from the current price of $54.28.
- Danimer Scientific (NYSE:DNMR) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating. They now have a $1.00 price target on the stock, down previously from $2.00. This represents a 154.5% upside from the current price of $0.39.
- Maravai LifeSciences (NASDAQ:MRVI) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $10.00 price target on the stock, down previously from $11.00. This represents a 17.9% upside from the current price of $8.48.
- Pacira BioSciences (NASDAQ:PCRX) was downgraded by analysts at Truist Financial Co. from a "buy" rating to a "sell" rating. They now have a $8.00 price target on the stock, down previously from $30.00. This represents a 36.7% downside from the current price of $12.64.
- Triumph Group (NYSE:TGI) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $15.00 price target on the stock, down previously from $19.00. This represents a 17.0% upside from the current price of $12.82.
- Warner Bros. Discovery (NASDAQ:WBD) was downgraded by analysts at Sanford C. Bernstein from an "outperform" rating to a "market perform" rating. They now have a $8.00 price target on the stock, down previously from $10.00. This represents a 15.3% upside from the current price of $6.94.
- ZoomInfo Technologies (NASDAQ:ZI) was downgraded by analysts at Daiwa Capital Markets from an "outperform" rating to a "neutral" rating. They now have a $9.00 price target on the stock, down previously from $15.00. This represents a 0.3% upside from the current price of $8.97.
- View today's most recent analysts' downgrades at MarketBeat.com
| Trading options? Avoid this mistake (ad) |
You may have heard the saying "options are risky" …
And, they can be. But only if you use them the way a lot of folks do.
A lot of people think of BUYING speculative options when they talk about options.
And BUYING low probability, speculative options is definitely risky…
It's how some folks leverage large sums of money hoping that a stock moves in the "right" direction over a certain period of time.
Click here to jump in on the next one |
|
- Artiva Biotherapeutics (NASDAQ:ARTV) is now covered by analysts at Needham & Company LLC. They set a "buy" rating and a $23.00 price target on the stock. This represents a 107.8% upside from the current price of $11.07.
- Artiva Biotherapeutics (NASDAQ:ARTV) is now covered by analysts at Wedbush. They set an "outperform" rating and a $18.00 price target on the stock. This represents a 62.6% upside from the current price of $11.07.
- Artiva Biotherapeutics (NASDAQ:ARTV) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.The current price is $11.07.
- Artiva Biotherapeutics (NASDAQ:ARTV) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $23.00 price target on the stock. This represents a 107.8% upside from the current price of $11.07.
- Artiva Biotherapeutics (NASDAQ:ARTV) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $21.00 price target on the stock. This represents a 89.7% upside from the current price of $11.07.
- iTeos Therapeutics (NASDAQ:ITOS) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $31.00 price target on the stock. This represents a 103.3% upside from the current price of $15.25.
- New York Mortgage Trust (NASDAQ:NYMT) is now covered by analysts at Janney Montgomery Scott. They set a "neutral" rating and a $7.00 price target on the stock. This represents a 13.6% upside from the current price of $6.16.
- Southern Missouri Bancorp (NASDAQ:SMBC) is now covered by analysts at Stephens. They set an "overweight" rating and a $60.00 price target on the stock. This represents a 18.8% upside from the current price of $50.51.
- Sable Offshore (NYSE:SOC) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $19.00 price target on the stock. This represents a 30.8% upside from the current price of $14.53.
- Veralto (NYSE:VLTO) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $118.00 price target on the stock. This represents a 10.0% upside from the current price of $107.24.
- Xylem (NYSE:XYL) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $165.00 price target on the stock. This represents a 28.0% upside from the current price of $128.95.
- Zapata Computing (NASDAQ:ZPTA) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $1.75 price target on the stock. This represents a 174.7% upside from the current price of $0.64.
- View today's most recent analysts' new coverage at MarketBeat.com
| Get 30 Days of MarketBeat All Access Free | | Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: |
| - Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. - Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. - Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
| START YOUR 30-DAY FREE TRIAL  |
|
| Upgrade Your Subscription |
Upgrade to MarketBeat All Access and receive your premium edition of MarketBeat Daily at 9:00 AM ET. | UPGRADE NOW |
|
View and add up to five holdings to your watchlist.
| VIEW MY PORTFOLIO |
|
Join MarketBeat's free stock discussion and trading idea group on Facebook.
| JOIN NOW |
|
|
Thank you for subscribing to MarketBeat! We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that's you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com. If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails. © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103 . United States. Today's Bonus Content: BITCOIN |
Apple Inc. (AAPL) 
Amazon.com, Inc. (AMZN) 
Alphabet Inc. (GOOGL) 
Meta Platforms, Inc. (META) 
Microsoft Co. (MSFT) 
No comments:
Post a Comment